Alx Oncology Holdings Inc (NASDAQ:ALXO) has a beta value of 1.03 and has seen 1.12 million shares traded in the last trading session. The company, currently valued at $84.75M, closed the last trade at $1.47 per share which meant it gained $0.06 on the day or 4.26% during that session. The ALXO stock price is -1112.93% off its 52-week high price of $17.83 and 19.05% above the 52-week low of $1.19. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.93 million shares traded. The 3-month trading volume is 680.78K shares.
The consensus among analysts is that Alx Oncology Holdings Inc (ALXO) is Buy stock at the moment, with a recommendation rating of 1.57. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 5 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Alx Oncology Holdings Inc (NASDAQ:ALXO) trade information
Sporting 4.26% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ALXO stock price touched $1.47 or saw a rise of 7.84%. Year-to-date, Alx Oncology Holdings Inc shares have moved -90.13%, while the 5-day performance has seen it change 20.49%. Over the past 30 days, the shares of Alx Oncology Holdings Inc (NASDAQ:ALXO) have changed 0.00%. Short interest in the company has seen 7.84 million shares shorted with days to cover at 11.81.
Wall Street analysts have a consensus price target for the stock at $23, which means that the shares’ value could jump 93.61% from current levels. The projected low price target is $14.0 while the price target rests at a high of $38.0. In that case, then, we find that the current price level is -2485.03% off the targeted high while a plunge would see the stock gain -852.38% from current levels.
Alx Oncology Holdings Inc (ALXO) estimates and forecasts
Figures show that Alx Oncology Holdings Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -88.30% over the past 6 months, with this year growth rate of 25.40%, compared to 18.00% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -50.98% over the past 5 years.
ALXO Dividends
Alx Oncology Holdings Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Alx Oncology Holdings Inc (NASDAQ:ALXO)’s Major holders
Insiders own 1.91% of the company shares, while shares held by institutions stand at 92.44% with a share float percentage of 94.25%. Investors are also buoyed by the number of investors in a company, with Alx Oncology Holdings Inc having a total of 145.0 institutions that hold shares in the company. The top two institutional holders are VENBIO PARTNERS LLC with over 9.7 million shares worth more than $58.49 million. As of 2024-06-30, VENBIO PARTNERS LLC held 19.3531% of shares outstanding.
The other major institutional holder is FMR LLC, with the holding of over 7.81 million shares as of 2024-06-30. The firm’s total holdings are worth over $47.12 million and represent 15.5923% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Small Cap Growth Fund and Fidelity Series Small Cap Opportunities Fund . As of Aug 31, 2024 , the former fund manager holds about 3.20% shares in the company for having 1.69 shares of worth $2.48 million while later fund manager owns 1.06 shares of worth $1.55 million as of Aug 31, 2024 , which makes it owner of about 2.00% of company’s outstanding stock.
